Get the Stockscreener App
1.34
1.52%
0.02
After Hours:
1.30
-0.04
-2.99%
Lexicon Pharmaceuticals Inc stock is traded at $1.34, with a volume of 1.86M.
It is up +1.52% in the last 24 hours and down -6.94% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
1.86M
Relative Volume:
0.80
Market Cap:
$486.95M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.675
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-10.07%
1M Performance:
-6.94%
6M Performance:
+118.38%
1Y Performance:
+73.64%
1-Day Range:
$1.28
$1.35
1-Week Range:
$1.28
$1.52
52-Week Range:
$0.2836
$1.66
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.34 | 479.69M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Why Lexicon Pharmaceuticals Inc. stock is considered a top pick2025 Stock Rankings & Daily Market Momentum Tracking - newser.com
Can Lexicon Pharmaceuticals Inc. stock deliver consistent earnings growthWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Will Lexicon Pharmaceuticals Inc. stock split attract more investorsBear Alert & Daily Price Action Insights - newser.com
Can Lexicon Pharmaceuticals Inc. stock resist market sell offs2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Can Lexicon Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05 - MarketScreener
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFs2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
How to manage a losing position in Lexicon Pharmaceuticals Inc.Analyst Upgrade & Verified Entry Point Signals - newser.com
Lexicon Pharmaceuticals at Jefferies London: Strategic Pipeline Progress By Investing.com - Investing.com Canada
Published on: 2025-11-16 06:10:48 - newser.com
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day - Traders Union
What the charts say about Lexicon Pharmaceuticals Inc. todayTake Profit & Real-Time Chart Breakout Alerts - newser.com
What MACD signals say about Lexicon Pharmaceuticals Inc.July 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Private Equity Firms in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 17% Last Week - 富途牛牛
Broker Revenue Forecasts For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Are Surging Higher - Yahoo Finance
Private equity firms among Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders, saw gain in holdings value after stock jumped 17% last week - simplywall.st
Lexicon signals 2026 INPEFA profitability and eyes pilavapadin Phase III advancement while expanding global partnerships - MSN
Lexicon Pharmaceuticals Files Prospectus for Stock Sale - MSN
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference - The Manila Times
[8-K] LEXICON PHARMACEUTICALS, INC. Reports Material Event | LXRX SEC FilingForm 8-K - Stock Titan
Applying Wyckoff theory to Lexicon Pharmaceuticals Inc. stockQuarterly Performance Summary & Daily Market Momentum Tracking - newser.com
Lexicon (LXRX) Unveils Promising Sotagliflozin Data at AHA 2025 - GuruFocus
Lexicon Pharmaceuticals Stock (LXRX) Opinions on Q3 Earnings and Clinical Data - Quiver Quantitative
Lexicon Pharmaceuticals, Inc. Announces Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure Without Diabetes Presented At American Heart Association Annual Scientific Sessions 2025 - MarketScreener
Lexicon Pharmaceuticals Reveals Positive Clinical Data for Sotagliflozin in Heart Failure Patients Without Diabetes at AHA 2025 - Quiver Quantitative
Lexicon (NASDAQ: LXRX) reports HFpEF gains without diabetes in 6-minute walk and KCCQ - Stock Titan
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM) - The Globe and Mail
Lexicon Pharmaceuticals unveils new data on cardiovascular SGLT1/2 inhibitor - Traders Union
Lexicon Pharmaceuticals’ Losses Shrink As Partnerships Pay Off - Finimize
Earnings call transcript: Lexicon Pharmaceuticals beats Q3 2025 forecasts By Investing.com - Investing.com Australia
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Lexicon: Q3 Earnings Snapshot - theheraldreview.com
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):